Moreover, a study of clinical breast cancer patients receiving neoadjuvant chemotherapy treatment (NACT) demonstrates that higher ADAM10 protein level before NACT was associated with poor response to NACT and shorter overall survival. Here, ADAM10 is linked to breast cancer.